Evidence map›Paper›PMID 40213697›Full record

ReviewFrontiers in pharmacology2025

Recent advances in the role of polysaccharides in liver diseases: a review.

Junfeng Wang, Hanxiang Wang, Xiawen Yang, Kaiping Wang, Yu Zhang

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. International journal of molecular sciences · 2026
    Article
  4. Frontiers in nutrition · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Junfeng WangDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hanxiang WangDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiawen YangDepartment of Pharmacy, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Kaiping WangHubei Key Laboratory of Nature Medicinal Chemistry and Resource Evaluation, Tongji Medical College of Pharmacy, Huazhong University of Science and Technology, Wuhan, China.
Yu ZhangDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver diseases are a serious health problem worldwide, especially with a sustained increase in the burden of it every year. However, drugs commonly used in patients have limited efficacy and serious adverse reactions associated with long-term use. Therefore, it is urgent to find effective and safe alternatives. Polysaccharides are currently considered promising alternatives to traditional drugs because of their extensive activity and low toxicity. This review investigated the studies on hepatoprotective polysaccharides over the past 6 years, detailing their hepatoprotective effects, potential mechanisms, and drug carrier applications. These findings suggest that polysaccharides have prominent preventive and therapeutic effects on various liver diseases such as drug-induced liver injury, alcoholic liver disease, hepatitis B, non-alcoholic fatty liver disease, liver fibrosis, and hepatocellular carcinoma. Its mechanism includes multiple aspects such as metabolic regulation, reduction of oxidative stress and inflammation, and regulation of gut microbiota. Furthermore, owing to the good physicochemical properties, polysaccharides have been applied in delivery systems for chemotherapy drugs and small molecule drugs. However, further research is essential on the bioavailability, structure-activity relationship, and more clinical evidence of polysaccharides. Continued exploration of polysaccharides will provide tremendous potential for the treatment of liver diseases.

Indexed as

drug carrierhepatoprotective effectsliver diseasesmechanismpolysaccharides

Identifiers

PMID40213697
PMCPMC11982827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.